MORI-ART-MUSEUM
The Mori Art Museum , Japan’s leading contemporary art museum located atop Tokyo’s landmark Roppongi Hills Mori Tower, following an extensive four-month upgrade, will reopen on Saturday, April 25 with an exhibition entitled Simple Forms: Contemplating Beauty , Mori Art Museum’s first collaboration with Centre Pompidou-Metz and Fondation d'entreprise Hermès. The exhibition will present the timeless, universal aesthetic of simple forms, from a prehistoric stone implement to dynamic installations by contemporary artists.
Upgrades to the Museum include several technological advancements that will accommodate the growing diversity of artistic expression. Such additions will enable Mori Art Museum to serve as a new model for art museums worldwide by reinforcing its creative, innovative approach to the principle of “Art + Life,” which relates art to all aspects of life for enriched societies.
In addition to staging a wide range of originally-curated exhibitions focused on international and contemporary themes, the Museum will newly launch three smaller program series -- MAM Collection , MAM Screen and MAM Research -- to offer visitors richer and deeper experiences with the diverse world of contemporary art.
In the time since Mori Art Museum opened in 2003, a tide of globalization has swept through the cultural sphere, particularly in art. Contemporary art markets are booming in Asia, and Asian art has established a strong presence at international auctions and art fairs. As global contemporary art becomes more diverse and complex, museums are faced with the challenge of how best to present the great variety, historical context and accessibility of this art form to the public.
Mori Art Museum, based on a revised Mission and Vision that it introduced upon its 10th anniversary and now backed with newly upgraded state-of-the-art facilities, looks forward to expanding its role and direction in the Japanese, Asian and global art scenes as a pioneer of contemporary art.
About the Mori Art Museum, Tokyo
Mori Art Museum opened in 2003 with the aim of becoming a pioneering international museum of contemporary art with special significance for Asia. Grounded in founder Minoru Mori’s firm belief that “culture shapes a city’s identity,” the Museum was opened symbolically on the top floor of Roppongi Hills Mori Tower skyscraper, a noted landmark of Tokyo. The Museum is dedicated to making contemporary art more accessible to all people through a variety of initiatives. For instance, it remains open daily (except Tuesdays) until 10 p.m. during exhibition periods, enabling students and office workers to visit on weeknights after school or work. Now, visitors arriving after 5 p.m. account for 30% of the Museum’s total visitors, which reflects the success of the Museum’s creation and promotion of a new lifestyle. To date, Mori Art Museum has attracted 13.5 million people from around the world, further enhancing its global status as a preeminent museum for contemporary art.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20150423006885/en/
Contact:
Mori Art Museum, Tokyo
Kayo Machino (Ms.)
+81-(0)3-6406-6111
pr@mori.art.museum
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
SBC Medical added to membership of Russell 3000® Index28.6.2025 01:30:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608244276/en/ Yoshiyuki Aikawa-Director (Chairman), CEO Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000®Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to
Altimetrik and SLK Software Join Forces to Create an AI-First Engineering Services Powerhouse27.6.2025 22:44:00 CEST | Press release
Altimetrik, a pure-play AI, Data and Digital engineering solutions company, today announced the signing of a definitive agreement to acquire SLK Software (“SLK”), a global technology services firm focused on delivering AI, intelligence automation and analytics solutions. The acquisition will further strengthen Altimetrik’s end-to-end enablement services and expand its customer reach, with a clear path to accelerate towards Altimetrik’s goal of reaching $1billion in annual revenue. The transaction remains subject to customary closing conditions and is expected to close in the second half of 2025. Financial details were not disclosed. Founded in 2000, SLK is recognized as a leader in the tech industry, and for its commitment to create innovative digital solutions. This strategic acquisition will significantly enhance the scale of Altimetrik’s capabilities, bringing together Altimetrik’s AI-first, platform-native engineering model and SLK’s full technology services stack that will further
Andersen Consulting udvider sine kompetencer inden for forretningstransformation med tilføjelsen af The Clearing27.6.2025 16:48:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin platform med samarbejdsfirmaet The Clearing, som er en managementkonsulentvirksomhed med speciale i organisatorisk omstilling og lederudvikling. The Clearing blev stiftet i 2009 og rådgiver kunder om komplekse udfordringer ved at afstemme ledelse, strategi, kultur og drift. Firmaet arbejder med føderale agenturer, virksomheder og nonprofitorganisationer med henblik på at skabe målbare forandringer på tværs af forskellige interessenter til gavn for en leders vision og strategi. Med dyb erfaring inden for flere sektorer, herunder national sikkerhed, sundhedspleje og finansielle tjenester, leder The Clearings unikke blanding af talent med ekspertise inden for organisationsudvikling, dataanalyse og visuel rådgivning forretningstransformationer i stor skala og arbejder sammen med kunder og eksperter for at sikre, at rådgivning omsættes til implementering. "Vi leverer transformative resultater, der ikke kun er i overensstemmelse med strategiske mål, men også
PRD Therapeutics Announces Initiation of First-in-Human Study for PRD00127.6.2025 16:00:00 CEST | Press release
PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia (HoFH) and metabolic dysfunction associated fatty liver disease (MASH/MASLD), today announced that the company recently initiated dosing in a First-in-Human (FIH) clinical trial of PRD001, a first-in-class SOAT2 (formerly known as ACAT2) selective inhibitor. “We are excited to initiate dosing in this clinical trial of PRD001. Many clinical trials have been conducted on SOAT1/2 dual or SOAT1 selective inhibitors, but this is the first clinical trial of an SOAT2 selective inhibitor” said Kanji Hosoda, Ph.D., CEO and co-founder of PRD Therapeutics. “Several results with SOAT1 or 2 knockout mice have been published, suggesting that knocking out or inhibiting only SOAT2 is crucial to demonstrate safety and efficacy. PRD001 is the world's first and only SOAT2-selective inhibitor and is expected to exhibit safety and efficacy in hu
STEMCELL Technologies Introduces STEMprep™ Tissue Dissociator System to Accelerate Research Discoveries27.6.2025 14:00:00 CEST | Press release
New instrument automates tissue processing for researchers in cancer, immunology and other science fields To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250627342791/en/ To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. “Tissue dissociation is incredibly important for making advancements in research fields, like cancer and immunology, yet
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum